1. Introduction
Bowel sounds (BS), also known as abdominal auscultatory signals, are produced by the movement of gas and fluid during peristalsis and segmentation within the gastrointestinal (GI) tract. These bowel sounds stem from regular physiological activity and have long aided clinicians in evaluating gut motility and identifying problems such as bowel obstruction, ileus, or gastrointestinal bleeding. However, traditional auscultation has its limitations: it can be affected by background noise, differences between observers, and the inherently subjective interpretation of sounds that are not well defined [
1].
Over the past decade, there has been a resurgence of interest in quantifying bowel sounds through digital sensors, signal processing, and artificial intelligence (AI) methods. Digital stethoscopes and wearable acoustic sensors have enabled continuous, high-resolution recording of bowel sounds in real-world settings. When combined with machine learning algorithms—particularly convolutional neural networks (CNNs), recurrent neural networks (RNNs), and transformers—these systems can now identify patterns that correlate with disease states in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis [
2,
3].
IBD is a chronic condition marked by cycles of relapse and remission, affecting millions around the world, and becoming more common in both Western and newly industrialized countries. Closely tracking disease activity and anticipating flares are crucial for managing treatment and reducing complications. Currently, assessment typically depends on colonoscopy, imaging, and serum or fecal biomarkers—methods that can be invasive, costly, or slow to reflect changes. As a result, there is a growing need for non-invasive, affordable, and real-time monitoring tools that can be used both in clinical settings and at home [
4].
Recent research has suggested that artificial intelligence (AI)-assisted analysis of bowel sounds (BS) may provide novel, non-invasive insights into inflammatory bowel disease (IBD). Early studies indicate that BS frequency, duration, and spectral patterns can differ between active disease, remission, and non-IBD controls, raising the possibility that BS monitoring could aid in distinguishing IBD from functional gastrointestinal disorders such as irritable bowel syndrome (IBS). While these findings are preliminary, they highlight a potential role for BS analysis as an adjunctive biomarker for flare detection and disease monitoring. If validated in larger cohorts, this approach could enable more personalized and less invasive strategies for IBD care [
5,
6]. As we explained in
Figure 1, the integration of AI-based bowel sound analysis with traditional diagnostics holds the potential to revolutionize inflammatory bowel disease (IBD) detection, monitoring, and personalized management.
Despite its promise, the field remains in its early stages of development. There is no unified pipeline for recording, segmenting, classifying, and interpreting BS data. Technical challenges include noise removal, data labeling, and inter-individual variability. Clinical barriers involve validation in large cohorts, regulatory approval, and integration into electronic health systems. Ethical concerns about data privacy and equity must also be addressed [
3,
7,
8,
9].
This review provides a comprehensive examination of how AI is utilized to analyze bowel sounds in IBD. We begin by explaining how bowel sounds are produced and why they are an essential feature of IBD. Next, we delve into the latest AI methods, examining various model types, datasets, and their performance in real-world settings. Finally, we outline a path for integrating these technologies into clinical practice, discuss current challenges, and highlight promising areas for future research.
A critical gap is the lack of consensus on automated bowel sound analysis methodologies and the absence of validated, clinically deployable systems for IBD diagnosis and management [
3,
8,
10]. While prior studies have explored acoustic processing techniques, integration with advanced artificial intelligence (AI) approaches—such as deep learning architectures capable of extracting complex, physiologically relevant features from noisy, real-world recordings—remains largely unexplored in the context of IBD [
10,
11,
12,
13]. Existing work has focused on feasibility in healthy subjects or general gastrointestinal conditions, but few have systematically addressed the unique challenges of IBD, such as disease heterogeneity, fluctuating activity, and the need for real-time, objective biomarkers [
10,
13,
14,
15].
The unique contribution of this manuscript is the integration of state-of-the-art AI methodologies (e.g., convolutional neural networks, self-attention models, and transformer-based architectures) with advanced acoustic signal processing to enable high-accuracy, non-invasive detection, characterization, and monitoring of IBD using bowel sounds [
10,
11,
13]. This approach directly addresses the unmet need for standardized, scalable, and clinically actionable tools, moving beyond proof-of-concept to demonstrate quantitative performance and clinical applicability in IBD cohorts—a domain where such integration is still in its infancy.
Beyond summarizing prior findings, this review critically evaluates the design rigor of the included studies—sample sizes and spectrum of participants, IBD subtype distribution, recording protocols, labeling strategy, validation methods, and external validity. Where possible, we contrast reported metrics with clinically meaningful thresholds and with gold standards (fecal calprotectin, colonoscopy/endoscopic scores), clarifying whether AI-based bowel sound analytics are currently positioned to replace or complement existing tools.
2. Methods
This review was conducted following the SANRA recommendations for narrative reviews. A structured search strategy was implemented in PubMed, Embase, Scopus, and Google Scholar between January 1995 and May 2025.
Search terms: “inflammatory bowel disease,” “Crohn’s disease,” “ulcerative colitis,” “bowel sounds,” “acoustic analysis,” “artificial intelligence,” “deep learning,” and “machine learning.”
Inclusion criteria:
Human studies reporting bowel sound acquisition with AI or signal-processing methods.
Studies comparing IBD with healthy controls or functional GI disorders (e.g., IBS)
English language publications.
Exclusion criteria:
Animal studies or in vitro acoustic experiments.
Non-English publications without translation.
Abstract-only conference proceedings without peer-reviewed manuscripts.
Titles and abstracts were screened by two reviewers independently. Data were extracted on study design, cohort characteristics (sample size, IBD subtype distribution), recording device and protocol, acoustic features, AI model type, validation methods, and reported performance metrics (accuracy, AUC, F1 score, sensitivity, specificity). Disagreements were resolved through discussion. No formal meta-analysis was performed, given heterogeneity in methodologies.
6. Methodological Approaches in the Existing Literature
Recent studies investigating artificial intelligence (AI) for bowel sound (BS) analysis in inflammatory bowel disease (IBD) employ diverse methodologies in terms of data acquisition, preprocessing, and model training. This section systematically reviews the experimental designs, recording protocols, and analytical techniques used across published works.
6.1. Study Populations and Clinical Contexts
Most studies use small to medium-sized cohorts, often combining healthy controls with patients experiencing IBD, irritable bowel syndrome (IBS), or post-operative gastrointestinal dysfunction.
Table 4 below gives a brief idea about the study and its sample size.
6.2. Data Acquisition Methods
AI-based bowel sound studies have employed diverse devices—from smartphone microphones and wearable T-shirts to chest sensors and piezoelectric belts—covering 5–120 min recordings across various abdominal sites (
Table 5).
6.3. Preprocessing and Feature Extraction
Most studies employ a combination of signal denoising and segmentation, followed by handcrafted or deep-learned feature extraction (
Table 6).
6.4. AI Models and Training Approaches
Various AI models—including logistic regression, SVMs, CNNs, RCNNs, transformers, and gradient boosting—have achieved high accuracy (85–91%), F1 scores (~0.71), and AUCs (≥0.83–0.89) for bowel sound detection and classification across different datasets and platforms.
Table 7 summarizes the AI models and the training approaches.
6.5. Evaluation and Reporting
Most studies employ the following:
Train/test split or cross-validation.
Metrics: accuracy, F1-score, ROC-AUC.
There is no external validation in most studies.
Lack of explainability: model interpretability tools (e.g., saliency maps) are rarely used.
Only a few studies reported robustness tests across
Future external validation should be structured around multi-center cohorts with ≥300 IBD patients across phenotypes (ileal vs. colonic, stricturing vs. inflammatory, pediatric vs. adult). Harmonized protocols for recording duration (≥30 min fasting and postprandial), sensor placement, and annotation standards are required. Minimal requirements for robust generalizability include (i) independent external test cohorts, (ii) stratification by IBD subtype and disease activity, and (iii) evaluation against gold-standard comparators (endoscopy, fecal calprotectin).
6.6. Summary Table of Methodologies in Key Studies
A number of representative studies have explored different data types, preprocessing strategies, and AI models for bowel sound analysis. As summarized in
Table 8, approaches range from smartphone-based CNN models [
43,
58], to wearable acoustic spotting combined with gradient boosting [
2], and transformer architectures applied to spectrogram inputs [
58]. Reported performance metrics vary from ~83% AUC in wearable gradient boosting systems to ~89–90% accuracy or AUC in CNN and transformer models, highlighting both the promise and heterogeneity of current methodologies.
8. Results
Artificial intelligence (AI)-powered bowel sound analysis is an emerging, non-invasive modality for diagnosing, characterizing, and managing inflammatory bowel disease (IBD). Recent advances in signal processing and feature extraction—such as Efficient-U-Net for high-resolution event spotting and spectrogram-based convolutional neural networks (CNNs) for classification—enable precise temporal localization and physiologically meaningful feature extraction from continuous, noisy recordings [
3,
10].
AI models for bowel sound analysis have demonstrated high diagnostic performance in IBD cohorts. Automated bowel sound analysis using wavelet transformations, multi-layer perceptrons, and autoregressive-moving-average models has achieved diagnostic accuracy rates of 90% or higher in differentiating IBD from healthy controls and other GI disorders [
9,
10]. Deep learning approaches, including hybrid convolutional and recursive neural networks, have reported accuracy > 93% and specificity > 97% for bowel sound event detection, which is crucial for clinical diagnosis [
10]. Smartphone-based CNN models have achieved a bowel sound detection accuracy of 88.9% and F-measure of 72.3% in cross-validation, with bowel motility prediction correlating at over 98% with manual labels [
43]. Spectrogram -CBB detector achieved approximately 91% accuracy for bowel sound detection in a 30-participant cohort, with consistent performance across subjects, supporting the feasibility of spectrogram-based deep learning for GI sound analysis [
49]. These results are consistent across multiple studies and platforms, supporting the robustness of AI-based acoustic analysis.
Key acoustic features—such as Mel-Frequency Cepstral Coefficients (MFCCs), spectral centroid, jitter/shimmer, and entropy—are consistently altered in IBD and irritable bowel syndrome (IBS), and their extraction enables accurate disease characterization [
3,
9]. The use of large, expertly annotated datasets is essential for model training and benchmarking, supporting generalizability and reproducibility [
3].
Diagnosis: High sensitivity and specificity (typically 85–97%) support the use of AI-powered bowel sound analytics as a non-invasive adjunct for IBD diagnosis, potentially reducing reliance on invasive procedures such as colonoscopy and fecal calprotectin testing [
3,
10,
64].
Disease Activity Monitoring: Real-time, objective assessment of bowel sounds enables continuous disease activity tracking, facilitating early detection of flares and response to therapy [
49,
62,
64,
68].
Treatment Management: Predictive models can stratify patients by risk and forecast response to biologics, supporting personalized treatment decisions [
14,
55,
62,
65].
Resource Optimization: Integration with wearable platforms and remote monitoring technologies can decrease the need for in-person visits, optimize resource utilization, and improve patient quality of life without compromising care standards [
55,
68].
Despite these advances, widespread clinical implementation requires further validation in diverse populations, harmonization of analytical methodologies, and integration into digital clinical workflows [
14,
49,
62,
64,
65]. Ongoing research should prioritize prospective studies, external validation, and the development of standardized reporting frameworks. ROC curves (
Figure 3) and forest plots (
Figure 4) collectively demonstrate the diagnostic performance and variability of AI models in bowel sound analysis.
While these values demonstrate strong technical feasibility, whether such performance is sufficient for clinical decision-making remains uncertain and is addressed in the Discussion.
9. Limitations
Small and homogeneous sample sizes—often comprising 16 to 100 participants, frequently with a predominance of healthy volunteers or pooled patients with Crohn’s disease and ulcerative colitis, without detailed phenotypic stratification—result in models that are highly susceptible to overfitting and lack external validity. This severely limits the generalizability of AI-based bowel sound analysis across diverse populations, including pediatric versus adult patients, those with perianal or ileal-predominant Crohn’s disease, and post-operative states such as ileostomy, as these subgroups are rarely represented or analyzed separately in current studies. As a result, model performance in these underrepresented groups is unknown and likely suboptimal [
3,
8].
Table 9 summarizes some common limitations.
The absence of gold-standard clinical endpoints—such as endoscopic indices (e.g., Simple Endoscopic Score for Crohn’s Disease, Mayo score), biomarkers (fecal calprotectin, C-reactive protein), and validated clinical activity scores (Harvey–Bradshaw Index)—in most studies prevents robust assessment of whether AI-detected bowel sound patterns truly reflect IBD pathophysiology or merely background motility variations. Without these reference standards, it is not possible to determine the clinical relevance or disease specificity of the detected acoustic features [
15].
Inconsistent recording protocols and hardware, including variability in sensor type, placement, recording duration, and patient condition (fasting vs. postprandial), further undermine replicability and comparability across studies, impeding the development of standardized, clinically actionable tools. The lack of external validation and limited model explainability (e.g., absence of interpretable outputs or saliency mapping) hinder clinician trust, slow regulatory approval, and restrict clinical adoption, as highlighted in recent reviews [
3,
8].
10. Conclusions
The current state of artificial intelligence-based bowel sound analysis for inflammatory bowel disease (IBD) demonstrates technical feasibility and early diagnostic potential, particularly with wearable devices and deep learning models. However, translating this into a clinically validated, non-invasive, and explainable monitoring tool still requires several critical steps.
Standardization of protocols is essential, as heterogeneity in sensor types, placement, recording duration, and patient conditions hampers reproducibility and cross-study comparison, making consensus protocols for data acquisition and annotation crucial for robust multi-center studies and regulatory acceptance [
3,
10,
44].
Multi-center data with gold-standard endpoints is needed, as current small, uniform cohorts limit validation of acoustic biomarkers [
5,
14].
Prospective trials are needed to validate AI-based bowel sound analysis, as no system has yet been tested in real-world workflows or been shown to improve clinical outcomes [
5,
49,
55,
66].
Model interpretability is essential for clinician trust and regulatory approval, requiring explainability techniques like saliency mapping or interpretable feature extraction for shared decision-making [
5,
55].
Compliance with ethical and regulatory standards (HIPAA, GDPR, FDA/CE) is mandatory, especially for wearable and home-based platforms. Privacy, data security, and informed consent are key challenges for continuous biometric monitoring [
55,
69,
70].
The literature highlights significant heterogeneity in sensor types, placement, recording duration, and patient conditions, which impedes reproducibility and cross-study comparison. Establishing consensus protocols for data acquisition and annotation is a prerequisite for robust multi-center studies and regulatory acceptance [
3,
12,
67].
Multi-center data collection, with linkage to endoscopic, imaging, and biomarker data, is necessary to ensure generalizability and clinical relevance. Most studies to date have small, homogeneous cohorts and lack gold-standard endpoints, such as endoscopic scores or fecal calprotectin, which limits the ability to validate acoustic biomarkers against actual disease activity [
50,
71].
Prospective clinical trial validation is necessary to demonstrate that AI-based bowel sound analysis can accurately predict flares, monitor therapy response, and ultimately improve patient outcomes. No current system has been tested in real-world workflows or been shown to impact clinical endpoints [
15,
50,
71,
72].
Model interpretability must be addressed to build clinician trust and facilitate regulatory approval. Incorporating explainability techniques—such as saliency mapping or interpretable feature extraction—will be crucial for integration into shared decision-making [
49,
65,
69,
70].